Oral GLP-1 weight loss market valued at $6.8 billion after two US pill approvals
Two oral GLP-1 options now exist for weight management, and a market report projects 38.2% annual growth in the category; the pills differ in trial results and in how they are taken.
The market for oral GLP-1 weight loss drugs was valued at $6.8 billion in 2025 and is projected to reach $92.4 billion by 2034, according to a market research report on the category [1]. The estimate comes after the FDA cleared the first two GLP-1 pills for weight management roughly three months apart: oral Wegovy on December 22, 2025, and Foundayo on April 1, 2026 [2].
Oral Wegovy is once-daily semaglutide 25 mg and was the first GLP-1 pill approved for weight management. It launched in the US in early January 2026 [2]. In the OASIS 4 trial, participants who stayed on treatment lost about 16.6% of body weight, a result described as comparable to the injectable version [2]. Foundayo is Eli Lilly's orforglipron, a small-molecule oral GLP-1 approved for adults with obesity, or with overweight plus a weight-related condition [2]. In the ATTAIN-1 trial, participants lost up to about 12.4% of body weight at 72 weeks, and the drug has no food or water timing restrictions, unlike peptide-based oral products [2].
The market report puts the category's compound annual growth rate at 38.2% from 2026 through 2034, with North America contributing $3.03 billion, or 44.5% of 2025 revenue [1]. Small-molecule non-peptide products — the class orforglipron belongs to — held the largest segment share at 42.3% in 2025 [1]. The report's data were verified as of April 2026, and it describes oral GLP-1s as among the fastest-growing categories in pharmaceuticals [1]. Projections of this kind are estimates, not guarantees.
The report ties the shift to convenience. It cites real-world data that roughly 30% to 40% of patients stop injectable GLP-1 therapy within the first six months, with injection aversion the most common reason in patient surveys, and physician survey data in which 78% of endocrinologists and 83% of primary care physicians said they would prescribe oral agents to a broader group of patients than they would injectables [1]. It also cites a 2024 Phase 2 trial in which orforglipron produced about 14.7% mean weight loss over 36 weeks [1]. That is a different trial from ATTAIN-1 and a different duration, so the two figures are not directly comparable.
Not every oral GLP-1 is a weight-loss drug. Higher-strength oral semaglutide sold as Ozempic tablets (1.5 mg, 4 mg and 9 mg) shares a label with Rybelsus and is a type 2 diabetes product, not a weight-management one [2]. Separately, the Wegovy label now includes a 7.2 mg once-weekly maintenance dose for adults who have tolerated 2.4 mg for at least four weeks; in the STEP UP trial it produced 18.7% mean weight loss at 72 weeks against 15.6% for 2.4 mg, with more gastrointestinal events (70.8% versus 61.2%) and more dysaesthesia, a pins-and-needles sensation, at 22.9% versus 6.0% [2]. Zepbound (tirzepatide) was approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug cleared for that condition [2].
Why it matters for patients
Two oral options exist where there were none a year earlier, and they are not interchangeable. In their pivotal trials, oral Wegovy was associated with about 16.6% weight loss and Foundayo with up to about 12.4%, but those trials used different designs, durations and populations, so the numbers cannot be lined up side by side [2]. Both are prescription drugs [2]. US list prices and insurance coverage for the two pills are not detailed in the market report [1].
The two pills also differ in routine: oral semaglutide is a peptide-based product, while orforglipron carries no food or water timing restrictions [2]. Side effects across the class are similar: nausea, diarrhea, vomiting and constipation, generally worst during dose escalation, and all approved incretin drugs carry a boxed warning about thyroid C-cell tumors [2]. Long-term safety data for the newest molecules are still being established as trials read out [2].
What happens next
Novo Nordisk filed CagriSema, a combination of cagrilintide and semaglutide, with the FDA on December 18, 2025, after REDEFINE 1 showed about 22.7% weight loss at 68 weeks; a decision is expected around late 2026 [2]. Eli Lilly's retatrutide and Boehringer Ingelheim and Zealand Pharma's survodutide are in Phase 3, with plausible filings in late 2026 or 2027 and US launches in 2027 or 2028 if reviews go smoothly [2]. Amgen's MariTide has Phase 3 readouts expected in 2027, which would put a US filing in 2028 at the earliest [2]. None of those three is approved, and products sold online under those names are unapproved research chemicals [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.